Dallas, Texas 11/19/2013 (Financialstrend) – Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) reported its operating results for the 2013 Q3. It reported GAAP net-income attributable to its common shareholders of $3.4M, or $0.16/ common share-diluted, and $5.1M, or $0.23/ common share-diluted, for the 3 and 9 months that ended 30th September 2013, respectively, in comparison to the GAAP net-loss attributable to the common shareholders of $2.3M, or $0.11/ common share-diluted & net-income attributable to its common shareholders of $25.6M, or $1.23/ common share-diluted, for the 3 and 9 months that ended 30th September, 2012, respectively. Included in this GAAP net income attributable to its common shareholders for the 9 months that ended 30th September 2012, was a $32.7M gain, net of tax, on the sale of the its credit-loan manager.
Monday’s trading
In Monday’s trading session, Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) rose by 16.87%. The shares opened at a price of $1.93, which touched the intraday high of $2.07 and headed to a close of $1.87. Around 5.87 million exchanged hands over the trading day and an average volume of 2.30 million shares were traded over a 30 day period. The 52-week low of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) shares is $0.04 and its 52-week high is $3.65. The company has a market capitalization of $98.91 million.
About the company
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) is a specialized asset-management company. It is involved in evaluating, originating services & managing investment opportunities via its real estate, commercial-finance & financial fund management-subsidiaries. It seeks to develop the investment funds for its outside investors, for which the company provides asset-management services, under the long-term management arrangements either via a contract with, or as a manager / general partner of its sponsored-investment funds. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) maintains an investment in the funds that are sponsored by it.